|
1
|
Fujita M, Itokawa H and Sashida Y:
Honokiol, a new phenolic compound isolated from the bark of
Magnolia obovata THUNB. Chem Pharm Bull. 20:212–213. 1972.
|
|
2
|
Li X, Yuan Z, Wang Y, Wang W and Shi J:
Recent advances of honokiol: Pharmacological activities, manmade
derivatives and structure-activity relationship. Eur J Med Chem.
272(116471)2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zhong C, Wang C, Li W, Li W, Chen X, Guo
J, Feng Y and Wu X: A derivative of honokiol HM568 has an
anti-neuroinflammatory effect in Parkinson's disease. Chem Biol
Interact. 403(111212)2024.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zhang Y, Zhang P, Zhang X and Liu Y: HH-A,
a modified honokiol, protects against cerebral ischemia/reperfusion
induced brain injury in rodent via Nrf2/HO-1 signaling pathways.
Naunyn Schmiedebergs Arch Pharmacol. 397:3389–3402. 2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Miao H, Cui W, Zhang T, Zhang Y, Zhang J,
Lou H and Fan P: Mitochondrial targeting derivatives of honokiol
enhanced selective antitumor activity in NCI-H446 cells and
decreased in vivo toxicity in Caenorhabditis elegans. Eur J Med
Chem. 264(115996)2024.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Arnold RE, Saska J, Mesquita-Ribeiro R,
Dajas-Bailador F, Taylor L, Lewis W, Argent S, Shao H, Houk KN and
Denton RM: Total synthesis, biological evaluation and biosynthetic
re-evaluation of Illicium-derived neolignans. Chem Sci.
15:11783–11793. 2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Dai SY, Qin WX, Yu S, Li C, Yang YH and
Pei YH: Honokiol and magnolol: A review of structure-activity
relationships of their derivatives. Phytochemistry.
223(114132)2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sasia C, Borgonetti V, Mancini C, Lori G,
Arbiser JL, Taddei ML and Galeotti N: The neolignan honokiol and
its synthetic derivative honokiol hexafluoro reduce
neuroinflammation and cellular senescence in microglia cells.
Cells. 13(1652)2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yang R, Fu X, Fan J, Wang T, Song J, Xu T,
Guo Y and Zhang SY: Semisynthesis and biological evaluation of
novel honokiol thioethers against colon cancer cells HCT116 via
inhibiting the transcription and expression of YAP protein. Bioorg
Med Chem. 107(117762)2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Pillai VB, Samant S, Sundaresan NR,
Raghuraman H, Kim G, Bonner MY, Arbiser JL, Walker DI, Jones DP,
Gius D and Gupta MP: Honokiol blocks and reverses cardiac
hypertrophy in mice by activating mitochondrial Sirt3. Nat Commun.
14(6656)2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Liu F, Zhang Y, Xia X, Han J and Cao L:
Honokiol induces ferroptosis in ovarian cancer cells through the
regulation of YAP by OTUB2. J Obstet Gynaecol Res. 50:864–872.
2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ma Q, Xu M, Jing X, Qiu J, Huang S, Yan H,
Yin L, Lou J, Zhao L, Fan Y and Qiu P: Honokiol suppresses the
aberrant interactions between renal resident macrophages and
tubular epithelial cells in lupus nephritis through the
NLRP3/IL-33/ST2 axis. Cell Death Dis. 14(174)2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cai X, Jiang X, Zhao M, Su K, Tang MH,
Hong F, Ye N, Zhang R, Li N, Wang L, et al: Identification of the
target protein and molecular mechanism of honokiol in
anti-inflammatory action. Phytomedicine. 109(154617)2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Grandi M, Boldrin F, Risato G, Grillini S,
Tiso N, Argenton F, Leonardi E, Tosatto S, Solaini G, Baracca A and
Giorgio V: Honokiol blocks tumor development and metastasis through
mitochondrion-targeted effects. Cell Death Dis.
17(186)2026.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wu SM, Jan YJ, Tsai SC, Pan HC, Shen CC,
Yang CN, Lee SH, Liu SH, Shen LW, Chiu CS, et al: Targeting histone
deacetylase-3 blocked epithelial-mesenchymal plasticity and
metastatic dissemination in gastric cancer. Cell Biol Toxicol.
39:1873–1896. 2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kim Y, Jang HD, An DH, Lee HS, Kim HG and
Choi SE: Honokiol inhibits colorectal cancer cell growth:
Involvement of Hsp27 as a molecular target. Curr Issues Mol Biol.
47(921)2025.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lee TY, Chang CC, Lu WJ, Yen TL, Lin KH,
Geraldine P, Li JY and Sheu JR: Honokiol as a specific collagen
receptor glycoprotein VI antagonist on human platelets: Functional
ex vivo and in vivo studies. Sci Rep. 7(40002)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Szymczyk J, Sochacka M, Biadun M,
Sluzalska KD, Witkowska D and Zakrzewska M: . Overcoming drug
resistance of cancer cells by targeting the FGF1/FGFR1 axis with
honokiol or FGF ligand trap. Front Pharmacol.
15(1459820)2024.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tian R, Yang J, Wang X, Liu S, Dong R,
Wang Z, Yang Z, Zhang Y, Cai Z, Yang H, et al: Honokiol acts as an
AMPK complex agonist therapeutic in non-alcoholic fatty liver
disease and metabolic syndrome. Chin Med. 18(30)2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Xiang F, Zhang Z, Li Y, Xia B, Liao Y,
Yang C, He Z, Lin L and Xie J: Honokiol targeting SIRT3: From
molecular mechanisms to therapeutic opportunities. FASEB J.
39(e70798)2025.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Li H, Sun J, Wu Y, Yang Y, Zhang W and
Tian Y: Honokiol relieves hippocampal neuronal damage in
Alzheimer's disease by activating the SIRT3-mediated mitochondrial
autophagy. CNS Neurosci Ther. 30(e14878)2024.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Liao Y, Ke B, Long X, Xu J and Wu Y:
Abnormalities in the SIRT1-SIRT3 axis promote myocardial
ischemia-reperfusion injury through ferroptosis caused by silencing
the PINK1/Parkin signaling pathway. BMC Cardiovasc Disord.
23(582)2023.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kim JE, Jo MJ, Bae SY, Ahn SY, Ko GJ and
Kwon YJ: Mitochondrial SIRT3 as a protective factor against
cyclosporine A-induced nephrotoxicity. Sci Rep.
14(10143)2024.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Qi XY, Yuan JD, Liu ZY, Jiang XQ, Zhang Q,
Zhang SL, Zhao L, Ke LY, Zhang CY, Li Y, et al: Sirtuin 3-mediated
deacetylation of superoxide dismutase 2 ameliorates sodium
fluoride-induced mitochondrial dysfunction in porcine oocytes. Sci
Total Environ. 908(168306)2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Li F, Ye C and Wang X, Li X and Wang X:
Honokiol ameliorates cigarette smoke-induced damage of airway
epithelial cells via the SIRT3/SOD2 signalling pathway. J Cell Mol
Med. 27:4009–4020. 2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chang Y, Wang C, Zhu J, Zheng S, Sun S, Wu
Y, Jiang X, Li L, Ma R and Li G: SIRT3 ameliorates
diabetes-associated cognitive dysfunction via regulating
mitochondria-associated ER membranes. J Transl Med.
21(494)2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hua KF, Hsu HT, Huang MS, Chiu HW, Wong
WT, Peng CH, Lin YB, Chen A, Wang CC, Hsu CH, et al: Honokiol
exhibits anti-NLRP3 inflammasome and antimicrobial properties in
neisseria gonorrhoeae-infected macrophages. J Inflamm Res.
17:3499–3513. 2024.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhou Q, Yi G, Chang M, Li N, Bai Y, Li H
and Yao S: Activation of Sirtuin3 by honokiol ameliorates alveolar
epithelial cell senescence in experimental silicosis via the
cGAS-STING pathway. Redox Biol. 74(103224)2024.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wang Z, Liu J, Mou Y, Zhou X, Liao W, Li Y
and Tang J: Disruption of cholesterol homeostasis triggers
NLRP3-cGAS-STING axis-dependent hepatic fibrosis and honokiol
intervention effects. Phytomedicine. 143(156904)2025.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Pan X, Hua Z, Fan G and Feng Q:
Inflammatory suppression and immunity regulation benefits of
honokiol in a rat model of acute peritonitis via the regulation of
NLRP3 inflammasome and Sirt1/autophagy axis. Histol Histopathol.
39:921–934. 2024.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhou Q, Chang M, Guo S, Zhang Y, Qu Q,
Zhou Q, Li Z and Yao S: Honokiol ameliorates silica-induced lung
fibrosis by inhibiting macrophage pyroptosis via modulating
cGAS/STING signaling. Int Immunopharmacol.
146(113812)2025.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wei Y, Hui VLZ, Chen Y, Han R, Han X and
Guo Y: YAP/TAZ: Molecular pathway and disease therapy. MedComm
(2020). 4(e340)2023.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wu KY, Liu L, Wu ZH, Huang Q, Xie RJ, Zhou
L and Wang M: Hinokiol regulates the cell cycle and apoptosis of
nasopharyngeal carcinoma CNE1 cells via Hippo-YAP signaling
pathway. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 59:621–629.
2024.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
34
|
Liu F, Zhang Y, Xia X, Han J and Cao L:
Honokiol regulates ovarian cancer cell malignant behavior through
YAP/TAZ pathway modulation. J Obstet Gynaecol Res. 50:1010–1019.
2024.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Khodir SA, Sweed EM, El-Haroun H,
Abd-Elhamid TH, El Derbaly SA, Mahmoud AR and Motawea SM: Honokiol
ameliorates reserpine-induced fibromyalgia through antioxidant,
anti-inflammatory, neurotrophic, and anti-apoptotic mechanisms. Sci
Rep. 15(25983)2025.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Fei Y, Zhang X, Wang X, Sun Y, He J, Liu
X, Song Z, Li L, Qiu L, Qian Z, et al: Upregulation of tumor
suppressor PIAS3 by Honokiol promotes tumor cell apoptosis via
selective inhibition of STAT3 tyrosine 705 phosphorylation. J Nat
Med. 78:285–295. 2024.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Chen X, Zhang M, Zhou F, Gu Z, Li Y, Yu T,
Peng C, Zhou L, Li X, Zhu D, et al: SIRT3 activator honokiol
inhibits Th17 cell differentiation and alleviates colitis. Inflamm
Bowel Dis. 29:1929–1940. 2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hu Y, Zhang M, Liu B, Tang Y, Wang Z, Wang
T, Zheng J and Zhang J: Honokiol prevents chronic cerebral
hypoperfusion induced astrocyte A1 polarization to alleviate
neurotoxicity by targeting SIRT3-STAT3 axis. Free Radic Biol Med.
202:62–75. 2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wang XH, Ning ZH, Xie Z, Ou Y, Yang JY,
Liu YX, Huang H, Tang HF, Jiang ZS, Hu HJ, et al: SIRT3/AMPK
signaling pathway regulates lipid metabolism and improves
vulnerability to atrial fibrillation in dahl salt-sensitive rats.
Am J Hypertens. 37:901–908. 2024.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wei X, Wang Y, Lao Y, Weng J, Deng R, Li
S, Lu J, Yang S and Liu X: Effects of honokiol protects against
chronic kidney disease via BNIP3/NIX and FUNDC1-mediated mitophagy
and AMPK pathways. Mol Biol Rep. 50:6557–6568. 2023.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Lin X, Zhang H, Chu Y, Zhang Y, Xu C, Xie
H, Ruan Q, Lin J, Huang CK and Chai D: Honokiol ameliorates
angiotensin II-induced cardiac hypertrophy by promoting
dissociation of the Nur77-LKB1 complex and activating the AMPK
pathway. J Cell Mol Med. 28(e18028)2024.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Chen Y, Yang Z, Bai J, Wang X, Yuan Q, Mi
Y and Zhang C: Bioactive lignan honokiol alleviates ovarian
oxidative stress in aging laying chickens by regulating SIRT3/AMPK
pathway. Antioxidants (Basel). 13(377)2024.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Chu Y, Gui S, Zheng Y, Zhao J, Zhao Y, Li
Y and Chen X: The natural compounds, Magnolol or Honokiol, promote
adipose tissue browning and resist obesity through modulating
PPARα/γ activity. Eur J Pharmacol. 969(176438)2024.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Zhang L, Guo R, Chen M, Liu M, Liu Y, Yu
Y, Zang J, Kong L and Li X: Inhibition of ovarian cancer growth,
metastasis and reverse the tumor microenvironment by dual
drug-loaded polymer micelle targeting tumor microenvironment. Int J
Nanomedicine. 20:2969–2990. 2025.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Guo C, Cheng X, Yang Y, Wang L, Wang W and
Shao L: Aptamer-modified GSH-degradable honokiol polyprodrug
nanoparticles for ovarian cancer-specific targeting therapy. Bioorg
Med Chem Lett. 123(130215)2025.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Wang B, Lv B, Li H, Zhang J, Ding Y, Zhou
J, Bu M, Fan L and Han C: Design of self-assembled micelles based
on natural dual-targeting strategies and evaluation of their
anti-liver cancer effects as drug delivery systems. NPJ Precis
Oncol. 9(82)2025.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Kim SY and Choi YH: Honokiol induces
paraptosis-like cell death through mitochondrial ROS-dependent
endoplasmic reticulum stress in hepatocellular carcinoma Hep3B
cells. Toxicol Res. 4:385–396. 2025.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Du Q, Zhang Q, Li J, Wang X, Gao X, Tan G,
Feng Q, Li J, Meng Y and Yu Y: Enhanced integrated therapy for
breast cancer employing Honokiol-loaded mesoporous polydopamine
nanoparticles in conjunction with photothermal effects and low-dose
metformin. APL Bioeng. 9(016115)2025.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Putra IMR, Lestari IA, Fatimah N, Hanif N,
Ujiantari NSO, Putri DDP and Hermawan A: Bioinformatics and in
vitro study reveal ERα as the potential target gene of honokiol to
enhance trastuzumab sensitivity in HER2+ trastuzumab-resistant
breast cancer cells. Comput Biol Chem. 111(108084)2024.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Han X, Cheng Y, Jiang Z, Alu A and Ma X:
Honokiol exhibits anti-tumor effects in breast cancer by modulating
the miR-148a-5p-CYP1B1 axis. Am J Chin Med. 52:1843–1861.
2024.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Mei M, Tang L, Zhou H, Xue N and Li M:
Honokiol prevents lung metastasis of triple-negative breast cancer
by regulating polarization and recruitment of macrophages. Eur J
Pharmacol. 959(176076)2023.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Gao Q, Sheng Q, Yang Z, Zhu Z, Li L, Xu L,
Xia J, Qiao Y, Gu J, Zhu X, et al: Honokiol-Magnolol-Baicalin
possesses synergistic anticancer potential and enhances the
efficacy of Anti-PD-1 immunotherapy in colorectal cancer by
triggering GSDME-dependent pyroptosis. Adv Sci (Weinh).
12(e2417022)2025.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Zhu Q, Zhang R, Gu X, Zhao Z, Gao Q, Chen
M, Wu Q, Xie T and Sui X: Honokiol enhances the sensitivity of
cetuximab in KRASG13D mutant colorectal cancer through destroying
SNX3-retromer complex. Theranostics. 14:5443–5460. 2024.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Cheng Y, Han X, Lai X and Wei X: Liposomal
honokiol inhibits non-small cell lung cancer progression and
enhances PD-1 blockade via suppressing M2 macrophages polarization.
Phytomedicine. 135(156093)2024.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Cheng X, Wang F, Qiao Y, Chen T, Fan L,
Shen X, Yu D, Huang Y and Wei M: Honokiol inhibits
interleukin-induced angiogenesis in the NSCLC microenvironment
through the NF-κB signaling pathway. Chem Biol Interact.
370(110295)2023.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Luo L, Wu T, Ji M, Xiang J, Zou Y and Liao
Y: Honokiol suppress the PD-L1 expression to improve anti-tumor
immunity in lung cancer. Int Immunopharmacol.
133(112098)2024.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Li BH, Ma H, Zhu J, Chen J, Dai YQ, Zhang
XJ, Li HM and Wu CZ: Semisynthesis and anti-cancer properties of
novel honokiol derivatives in human nasopharyngeal carcinoma CNE-2Z
cells. J Enzyme Inhib Med Chem. 38(2244694)2023.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Liao KS, Lee YR, Chao WY, Huang YJ, Chung
HC, Chen SH, Li YZ, Zhao PW and Chang HY: Honokiol suppresses cell
proliferation and tumor migration through ROS in human anaplastic
thyroid cancer cells. Endocr Metab Immune Disord Drug Targets: Apr
24, 2024 (Epub ahead of print).
|
|
59
|
Rawat L, Balan M, Sasamoto Y, Sabarwal A
and Pal S: A novel combination therapy with Cabozantinib and
Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth
through increased oxidative stress. Redox Biol.
68(102945)2023.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Singh L and Singh S: Neuroprotective
potential of Honokiol in ICV-STZ induced neuroinflammation, Aβ
(1-42) and NF-kB expression in experimental model of rats. Neurosci
Lett. 799(137090)2023.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Youn K and Jun M: Determination of
potential lead compound from magnolia officinalis for Alzheimer's
disease through pharmacokinetic prediction, molecular docking,
dynamic simulation, and experimental validation. Int J Mol Sci.
25(10507)2024.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Wang H, Liu J, Tian YR, Zhu F and Li H:
The effects of Honokiol on the liver of Alzheimer's disease mice by
upregulating SIRT3. J Alzheimers Dis. 107:641–652. 2025.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Liu G, Zhang T, Qian S, Zhang X, Lou H and
Fan P: Conjugation with the XJB peptide enhanced neuroprotective
effect of honokiol via SIRT3 modulation. Eur J Med Chem.
289(117460)2025.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Le DTT, Vu CM, Ly TTB, Nguyen NT, Nguyen
PTM and Chu HH: Effect of Honokiol on culture time and survival of
Alzheimer's disease iPSC-derived neurons. Bioimpacts.
14(27652)2024.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Cheng G, Hardy M, Feix JB and Kalyanaraman
B: Inhibition of levodopa metabolism to dopamine by honokiol
short-chain fatty acid derivatives may enhance therapeutic efficacy
in Parkinson's disease. Sci Rep. 15(20004)2025.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Cheng G, Hardy M, Hillard CJ, Feix JB and
Kalyanaraman B: Mitigating gut microbial degradation of levodopa
and enhancing brain dopamine: Implications in Parkinson's disease.
Commun Biol. 7(668)2024.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Cao W, Chen Z, Lin C, Lin X, Chen Y and
Zhang J: Honokiol mitigates metabolic-associated fatty liver
disease by regulating Nrf2 and RIPK3 signaling pathways. Turk J
Gastroenterol. 35:551–559. 2024.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Zhai T, Wang J and Chen Y: Honokiol
affects the composition of gut microbiota and the metabolism of
lipid and bile acid in methionine-choline deficiency diet-induced
NASH mice. Sci Rep. 13(15203)2023.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Rather IA, Khan N, Kushwah AS, Surampalli
G and Kumar M: Nephroprotective effects of honokiol in a high-fat
diet-streptozotocin rat model of diabetic nephropathy. Life Sci.
320(121543)2023.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Lin K, Wang A, Zhai C, Zhao Y, Hu H, Huang
D, Zhai Q, Yan Y and Ge J: Semaglutide protects against
diabetes-associated cardiac inflammation via Sirt3-dependent RKIP
pathway. Br J Pharmacol. 182:1561–1581. 2025.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Shi J, Liu M, Zhao J, Tan Y and Jiang C:
Honokiol protects against diabetic retinal microvascular injury via
sirtuin 3-mediated mitochondrial fusion. Front Pharmacol.
15(1485831)2024.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Tang H, Zhou Y, Ma L, Ye Y, Xiao QX, Tang
JQ and Xu Y: SIRT3 alleviates mitochondrial dysfunction and
senescence in diabetes-associated periodontitis by deacetylating
LRPPRC. Free Radic Biol Med. 227:407–419. 2025.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Sun H, Liu Y, Wang X and Shu L: A network
pharmacology-based method to explore the therapeutic effect of
honokiol on diabetes with comorbid depression in mice. Eur J
Pharmacol. 975(176642)2024.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Szałabska-Rąpała K, Zych M, Borymska W,
Londzin P, Dudek S and Kaczmarczyk-Żebrowska I: Beneficial effect
of honokiol and magnolol on polyol pathway and oxidative stress
parameters in the testes of diabetic rats. Biomed Pharmacother.
172(116265)2024.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Liu Y, Chen M, Zhu C and Guo D:
Transcriptome analysis of serum biomarker, shared gene signature
and pharmacological targets between diabetic cardiomyopathy and
nephropathy. Biochem Biophys Rep. 43(102194)2025.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Zhao Y, Lu Z, Zhang H, Wang L, Sun F, Li
Q, Cao T, Wang B, Ma H, You M, et al: Sodium-glucose exchanger 2
inhibitor canagliflozin promotes mitochondrial metabolism and
alleviates salt-induced cardiac hypertrophy via preserving SIRT3
expression. J Adv Res. 70:255–269. 2025.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Niu L, Wang S, Xu Y, Zu X, You X, Zhang Q,
Zhuang P, Jiang M, Gao J, Hou X, et al: Honokiol targeting ankyrin
repeat domain of TRPV4 ameliorates endothelial permeability in mice
inflammatory bowel disease induced by DSS. J Ethnopharmacol.
325(117825)2024.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Sun N, Zhi Z, Xiao T, Deng X, He T, Dong
W, Feng S, Chen S, Wong WL and Yuan W: The study of honokiol as a
natural product-based antimicrobial agent and its potential
interaction with FtsZ protein. Front Microbiol.
15(1361508)2024.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Ren S, Yang Y, Xia M, Deng Y, Zuo Y, Lei L
and Hu T: A Chinese herb preparation, honokiol, inhibits
Streptococcus mutans biofilm formation. Arch Oral Biol.
147(105610)2023.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Lin S, Li X, Zhang W, Shu G,
Tolker-Nielsen T, Li H, Xu F, Lin J, Peng G, Zhang L and Fu H:
Enhanced penetration and biofilm eradication by sophorolipid
micelles encapsulating Honokiol: A comprehensive solution for
biofilm-associated lung infections. J Nanobiotechnology.
23(76)2025.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Zheng S, Deng R, Huang G, Ou Z and Shen Z:
Effects of honokiol combined with resveratrol on bacteria
responsible for oral malodor and their biofilm. J Oral Microbiol.
16(2361402)2024.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Zhao Y, Yu S, Ye W, Lin G, Gao D and Zhang
J: Mechanistic insights into the dual anti-COVID-19 and
anti-inflammatory actions of Zhengqi tablets. J Ethnopharmacol.
352(120249)2025.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Yang F, Yang B, Song K, Jin Y, Wang G, Li
P, Yu Q and Ling F: Natural product honokiol exhibits antiviral
effects against Micropterus salmoides rhabdovirus (MSRV) both in
vitro and in vivo. J Fish Dis. 47(e13915)2024.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Salgado-Benvindo C, Leijs AA, Thaler M,
Tas A, Arbiser JL, Snijder EJ and van Hemert MJ: Honokiol inhibits
SARS-CoV-2 replication in cell culture at a post-entry step.
Microbiol Spectr. 11(e0327322)2023.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Sampieri-Morán JM, Bravo-Alfaro DA,
Uribe-Lam E, Luna-Barcenas G, Montiel-Sánchez M, Velasco-Rodríguez
LDC, Acosta-Osorio AA, Ferrer M and García HS: Delivery of Magnolia
bark extract in nanoemulsions formed by high and low energy methods
improves the bioavailability of Honokiol and Magnolol. Eur J Pharm
Biopharm. 208(114627)2025.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Liu C, Cao Z, Li L, Li Q, Zhang C, Wang Y,
Li L and Fu P: Self-Assembled Pt/Honokiol nanomicelles for the
treatment of sepsis-associated acute kidney injury. ACS Biomater
Sci Eng. 11:383–401. 2025.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Thakur NS, Rus I, Herbert A, Zallocchi M,
Chakrabarty B, Joshi AD, Lomeo J and Agrahari V: Crosslinked-hybrid
nanoparticle embedded in thermogel for sustained co-delivery to
inner ear. J Nanobiotechnology. 22(482)2024.PubMed/NCBI View Article : Google Scholar
|
|
88
|
He Y, Guo J, Ding H, Lin M, Wu Y, He Z,
Wang Z, Xia Q, Zhu C, Zhang Y and Feng N: Glutathione-responsive
CD-MOFs co-loading honokiol and indocyanine green biomimetic active
targeting to enhance photochemotherapy for breast cancer. Int J
Pharm. 660(124310)2024.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Liao D, Yang Y, Xiong S, Feng J, Zou C,
Peng H, Yang X, Zhang SL, Wang ZP, He Y and Huang C: Self-assembled
GSH-responsive polycyclophosphazene loaded honokiol nano-drug for
enhanced cancer therapy. Colloids Surf B Biointerfaces.
255(114876)2025.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Talbott SM, Talbott JA and Pugh M: Effect
of Magnolia officinalis and Phellodendron amurense (Relora®) on
cortisol and psychological mood state in moderately stressed
subjects. J Int Soc Sports Nutr. 10(37)2013.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Lin J, Liu H, Huang X and Deng Y:
Toxicological effects of Honokiol on zebrafish and its underlying
mechanism. J Biochem Mol Toxicol. 38(e23789)2024.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Sorkin BC, Kuszak AJ, Bloss G, Fukagawa
NK, Hoffman FA, Jafari M, Barrett B, Brown PN, Bushman FD, Casper
SJ, et al: Improving natural product research translation: From
source to clinical trial. FASEB J. 34:41–65. 2020.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Fanelli D, Costas R and Ioannidis JP:
Meta-assessment of bias in science. Proc Natl Acad Sci USA.
114:3714–3719. 2017.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Fried LE and Arbiser JL: Honokiol, a
multifunctional antiangiogenic and antitumor agent. Antioxid Redox
Signal. 11:1139–1148. 2009.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Yang J, Pei H, Luo H, Fu A, Yang H, Hu J,
Zhao C, Chai L, Chen X, Shao X, et al: Non-toxic dose of liposomal
honokiol suppresses metastasis of hepatocellular carcinoma through
destabilizing EGFR and inhibiting the downstream pathways.
Oncotarget. 8:915–932. 2017.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Zhang Q, Ye X, Wang L, Peng B, Zhang Y,
Bao J, Li W, Wei J, Wang A, Jin H and Chen S: Embryo-fetal
development toxicity of honokiol microemulsion intravenously
administered to pregnant rats. Regul Toxicol Pharmacol. 74:117–122.
2016.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Sarrica A, Kirika N, Romeo M, Salmona M
and Diomede L: Safety and toxicology of magnolol and honokiol.
Planta Med. 84:1151–1164. 2018.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Eliaz I and Weil E: Intravenous honokiol
in drug-resistant cancer: two case reports. Integr Cancer Ther.
19(1534735420922615)2020.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Qin X, Yin J, Zhang W, Li J, Wen J and
Chen S: Acute and subchronic toxicities in dogs and genotoxicity of
honokiol microemulsion. Regul Toxicol Pharmacol. 95:362–370.
2018.PubMed/NCBI View Article : Google Scholar
|
